Calls for papers
-
According to Glenmark, the FDA has approved the company’s sNDA to extend the use of Ryaltris olopatadine / mometasone nasal spray for the treatment of seasonal allergic rhinitis to patients aged 6 -12. Ryaltris was… Read more . . .
-
Eli Lilly and Company has agreed to pay approximately $2.8 billion up front and up to an additional $1 billion in milestone payments for pyschedelics developer AtaiBeckley, the companies said. AtaiBeckley’s lead candidate is BPL-003… Read more . . .
-
Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… Read more . . .
-
According to Texas-based CDMO Matica Biotechnology, the company will provide development and manufacturing services to vaccine developer VaxDome, also based in Texas, to advance a VaxDome intranasal antiviral / vaccine candidate into clinical trials. Matica… Read more . . .
-
According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… Read more . . .
-
ARS Pharmaceuticals, whose only product is neffy epinephrine nasal spray, announced that long-time CEO Richard Lowenthal has left the company and that Donn Casale, has taken over as CEO and Director. Casale joined ARS Pharma… Read more . . .
-
Nebulizer developer Nebu-Flow, which recently received a £2 million Scottish Enterprise grant, announced that it has been invited to join the Innovate UK Scaleup Programme, which will provide access to a “virtual executive team.” The… Read more . . .
-
The Australian Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative is providing over AU $15 million to Atisama Therapeutics (formerly Rage Bio) and Monash University to support continued development of RB042 inhaled… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… Read more . . .
-
Insmed has hired former Johnson & Johnson executive Samuele Butera as Senior VP, General Manager, Global Respiratory, the company said. Butera previously served in executive positions at Sandoz and Novartis before joining Johnson & Johnson,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden